Pharvaris NVPHVS -2.39%22 Quick Ratio is 11.24 as of Mar. 2026, which is 12% below its 10-year median of 12.72. GuruFocus rates PHVS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, Pharvaris NV ranks better than 81.21% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Pharvaris NV's quick ratio for the quarter that ended in Mar. 2026 was 11.24.
Pharvaris NV has a quick ratio of 11.24. It generally indicates good short-term financial strength.
The historical rank and industry rank for Pharvaris NV's Quick Ratio or its related term are showing as below:
PHVS'
s Quick Ratio Range Over the Past 10 Years
Min: 7.96 Med: 12.72 Max: 34.61
Current: 11.24
During the past 9 years, Pharvaris NV's highest Quick Ratio was 34.61. The lowest was 7.96. And the median was 12.72.
PHVS's Quick Ratio is ranked better than 81.21% of 1410
companies
in the Biotechnology industry
Industry Median: 3.6
vs PHVS: 11.24
Pharvaris NV (NAS:PHVS) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Pharvaris NV Quick Ratio Related Terms
Pharvaris NV Quick Ratio Historical Data
* Premium members only.
The historical data trend for Pharvaris NV's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharvaris NV's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharvaris NV Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharvaris NV's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Pharvaris NV's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Pharvaris NV's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharvaris NV (PHVS) has a Quick Ratio of 11.24 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Pharvaris NV and its competitors. This is 12% below median its historical median of 12.72. Over the past decade, Pharvaris NV's Quick Ratio has ranged from 7.96 to 34.61. According to the industry distribution chart, Pharvaris NV ranks #265 out of 1410 companies in the Biotechnology industry, placing it in the top 18.8%.
Is Pharvaris NV's Quick Ratio too high?
Pharvaris NV's current Quick Ratio of 11.24 is 12% below median its 10-year median of 12.72. Over the past 10 years, this metric has ranged from a low of 7.96 to a high of 34.61. The Biotechnology industry median Quick Ratio is 3.60. Pharvaris NV's value of 11.24 is 212.2% above this industry median. Based on the distribution chart, Pharvaris NV ranks #265 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharvaris NV has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's Quick Ratio compare to BHVN and NRIX?
According to the Biotechnology industry distribution chart, Pharvaris NV ranks #265 out of 1410 companies for Quick Ratio. This places Pharvaris NV in the top 19% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Pharvaris NV's value of 11.24 is 212.2% above this benchmark. Historically, Pharvaris NV's own Quick Ratio has ranged from 7.96 to 34.61 over the past decade. While the company's 10-year median is 12.72 vs. the industry median of 3.60, Pharvaris NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharvaris NV's current Quick Ratio of 11.24 is 212.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Pharvaris NV and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharvaris NV's current Quick Ratio is 11.24, which is 12% below median its own 10-year median of 12.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (PHVS) has a current Quick Ratio of 11.24. The current Quick Ratio is 11.24, which is 12% below median its 10-year median of 12.72 and 212.2% above the Biotechnology industry median of 3.60. Pharvaris NV's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Pharvaris NV (PHVS), the current Quick Ratio is 11.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
22GF Score
Get the complete analysis for PHVS
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHVS has been successfully added to your 
